Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of PRO1286 in advanced solid tumors
CTR20250215Phase 2Terminated
- Sponsor
- ProfoundBio
- Start
- Dec 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GEN1286 in Nonhematologic neoplasms, sponsored by ProfoundBio. Started Dec 2024; status: terminated.
02
Drugs
GEN1286
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20250215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250215.